Mounira El Demery1, Gaiané Demirdjian-Sarkissian2, Simon Thezenas3, William Jacot4, Yassine Laghzali3, Bruno Darbouret2, Stéphane Culine5, Xavier Rebillard6, Pierre-Jean Lamy7. 1. Department of Medical Oncology, Cap d¿Or Clinic, La Seyne sur Mer, France. 2. Clinical Diagnostic Division, Thermo Fisher Scientific, Nimes, France. 3. Department of Biostatistics, Institut Régional du Cancer de Montpellier (ICM), Val d¿Aurelle, Montpellier, France. 4. Department of Medical Oncology, Institut Régional du Cancer de Montpellier (ICM), Val d¿Aurelle, Montpellier, France. 5. Hôpital Saint-Louis, APHP, Saint-Louis, France. 6. Clinique Beausoleil, Montpellier, France. 7. Department of Biology and Oncogenetics, Institut Régional du Cancer de Montpellier (ICM), Val d¿Aurelle, Montpellier, 34298, France.
Abstract
BACKGROUND: Urine markers have been studied extensively but there is a lack of blood prognostic markers in bladder cancer. MMP-7 is produced by stromal cells and by tumor cells and is overexpressed in a variety of epithelial and mesenchymal tumors. In this study, we assessed with an immunoassay we developed, the prognostic value of serum MMP-7 in a series of patients with advanced bladder cancer. METHODS: Serum samples were collected from 56 patients with advanced bladder cancer who were treated at the Montpellier Cancer Institute between March 2003 and December 2004. MMP-7 was quantified in serum samples by using a homogeneous sandwich fluoroimmunoassay we developed based on the time resolved amplified cryptate emission (TRACE) technology. RESULTS: The median overall survival of the study population was 2.2 years (95% CI, 1.4 to 3.0) with 1- and 5-year survival rates of 73% (95% CI, 59% to 82%) and 25% (95% CI, 14% to 37%), respectively. High MMP-7 serum levels were associated with poor survival. Using a cut-off value of 11.5 ng/mL, the median overall survival was 3.0 years (95% CI, 1.5 to 5.1) for patients with MMP-7 serum level <11.5 ng/mL and 1.3 years (95% CI, 0.8 to 2.5) for patients with serum level ?11.5 ng/mL. Multivariate analysis identified high MMP-7 serum concentration as an independent prognostic factor for survival in patients with advanced bladder cancer (R?=?2.1, 95% CI, 1.1 to 4.4). CONCLUSIONS: Our results show that the MMP-7 serum concentration is an independent prognostic factor in patients with locally advanced and or metastatic bladder cancer.
BACKGROUND: Urine markers have been studied extensively but there is a lack of blood prognostic markers in bladder cancer. MMP-7 is produced by stromal cells and by tumor cells and is overexpressed in a variety of epithelial and mesenchymal tumors. In this study, we assessed with an immunoassay we developed, the prognostic value of serum MMP-7 in a series of patients with advanced bladder cancer. METHODS: Serum samples were collected from 56 patients with advanced bladder cancer who were treated at the Montpellier Cancer Institute between March 2003 and December 2004. MMP-7 was quantified in serum samples by using a homogeneous sandwich fluoroimmunoassay we developed based on the time resolved amplified cryptate emission (TRACE) technology. RESULTS: The median overall survival of the study population was 2.2 years (95% CI, 1.4 to 3.0) with 1- and 5-year survival rates of 73% (95% CI, 59% to 82%) and 25% (95% CI, 14% to 37%), respectively. High MMP-7 serum levels were associated with poor survival. Using a cut-off value of 11.5 ng/mL, the median overall survival was 3.0 years (95% CI, 1.5 to 5.1) for patients with MMP-7 serum level <11.5 ng/mL and 1.3 years (95% CI, 0.8 to 2.5) for patients with serum level ?11.5 ng/mL. Multivariate analysis identified high MMP-7 serum concentration as an independent prognostic factor for survival in patients with advanced bladder cancer (R?=?2.1, 95% CI, 1.1 to 4.4). CONCLUSIONS: Our results show that the MMP-7 serum concentration is an independent prognostic factor in patients with locally advanced and or metastatic bladder cancer.
Authors: Tracy Vargo-Gogola; Howard C Crawford; Barbara Fingleton; Lynn M Matrisian Journal: Arch Biochem Biophys Date: 2002-12-15 Impact factor: 4.013
Authors: D F Bajorin; P M Dodd; M Mazumdar; M Fazzari; J A McCaffrey; H I Scher; H Herr; G Higgins; M G Boyle Journal: J Clin Oncol Date: 1999-10 Impact factor: 44.544
Authors: Tibor Szarvas; Markus Becker; Frank vom Dorp; Carolin Gethmann; Martin Tötsch; Agnes Bánkfalvi; Kurt W Schmid; Imre Romics; Herbert Rübben; Süleyman Ergün Journal: Cancer Sci Date: 2010-01-20 Impact factor: 6.716
Authors: Tibor Szarvas; Tobias Jäger; Markus Becker; Stephan Tschirdewahn; Christian Niedworok; Ilona Kovalszky; Herbert Rübben; Süleyman Ergün; Frank vom Dorp Journal: Pathol Oncol Res Date: 2011-01-21 Impact factor: 3.201
Authors: Richard J Sylvester; Adrian P M van der Meijden; Willem Oosterlinck; J Alfred Witjes; Christian Bouffioux; Louis Denis; Donald W W Newling; Karlheinz Kurth Journal: Eur Urol Date: 2006-01-17 Impact factor: 20.096
Authors: Tibor Szarvas; Bernhard B Singer; Markus Becker; Frank Vom Dorp; Tobias Jäger; Attila Szendroi; Péter Riesz; Imre Romics; Herbert Rübben; Süleyman Ergün Journal: BJU Int Date: 2010-09-03 Impact factor: 5.588
Authors: Joan Maurel; Cristina Nadal; Xabier Garcia-Albeniz; Rosa Gallego; Enric Carcereny; Vanesa Almendro; Maribel Mármol; Elena Gallardo; Josep Maria Augé; Raquel Longarón; Alex Martínez-Fernandez; Rafael Molina; Antoni Castells; Pere Gascón Journal: Int J Cancer Date: 2007-09-01 Impact factor: 7.396
Authors: Azizbek Ramankulov; Michael Lein; Manfred Johannsen; Mark Schrader; Kurt Miller; Klaus Jung Journal: Cancer Sci Date: 2008-04-14 Impact factor: 6.716
Authors: J Y Liu; Y B Dai; X Li; K Cao; D Xie; Z T Tong; Z Long; H Xiao; M K Chen; Y L Ye; B Liu; J Tan; J Tang; Z Z Xu; Y Gan; Y H Zhou; F Deng; L Y He Journal: Cell Death Dis Date: 2017-03-23 Impact factor: 8.469
Authors: Petra Terézia Kovács; Tamás Mayer; Anita Csizmarik; Melinda Váradi; Csilla Oláh; Ádám Széles; Stephan Tschirdewahn; Ulrich Krafft; Boris Hadaschik; Péter Nyirády; Péter Riesz; Tibor Szarvas Journal: Biomedicines Date: 2022-03-17